CT with contrast
Chest, abdomen and pelvis staging and follow-up. Records contrast volume, phase timing, slice thickness and RECIST 1.1 target-lesion diameters.
Every request stores the patient, category, modality, body region, priority, the protocol it follows and the person who reported it. Results carry findings, an impression, measured values with reference ranges, and a review status before a patient can see them.
Chest, abdomen and pelvis staging and follow-up. Records contrast volume, phase timing, slice thickness and RECIST 1.1 target-lesion diameters.
Brain, pelvis, liver and spine. Records sequence set, contrast dose, isotropic resolution and RANO response category for CNS disease.
Whole-body metabolic assessment. Records fasting glucose, injected activity, uptake time and SUVmax per lesion.
Breast, neck, abdomen and image-guided biopsy support. Records probe, lesion dimensions and elastography where used.
CEA, CA 19-9, CA 125, AFP, PSA, beta-hCG and LDH with assay reference interval and delta against the previous value.
Full blood count, renal and liver panels — the safety baseline before contrast studies and cytotoxic cycles.
Grade, margins, lymphovascular invasion, ER/PR/HER2, Ki-67, PD-L1 and mismatch repair protein status.
Immunophenotyping for haematological tumours with marker panels and blast counts.
52-gene solid tumour panel from FFPE tissue. Records tumour cellularity, mean coverage, variant allele frequency and AMP/ASCO/CAP tier.
BRCA1/2, PALB2 and Lynch syndrome genes with copy-number analysis, reported alongside counselling status.
EGFR, KRAS, BRAF, ALK, ROS1 and NTRK by PCR, FISH or RNA fusion panel for targeted therapy decisions.
Immunotherapy eligibility markers reported with the assay's cut-off values.
Live records, result entry and review sign-off live inside the dashboards.
Sign in to a dashboard